Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a 'Buy' rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained an $88 price target.
November 01, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a 'Buy' rating on CRISPR Therapeutics and maintained an $88 price target.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of an $88 price target indicates a positive outlook for CRISPR Therapeutics. This could potentially lead to an increase in investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100